EN DE
STOCK COMPARISON

GMT vs Abbott Laboratories: Fair Value & Quality

Both stocks run through our valuation models. Here is how GMT (GMT) and Abbott Laboratories (ABT) compare, as of Aug 21, 2026.

As of Aug 21, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: GMT trades at PLN 3.68 versus a fair value of PLN 0.39 (-89%), while Abbott Laboratories trades at $114 versus $74.79 (-34%).
GMT
GMT.WAR · PLN · Health Care
-89%
upside to fair value
overvalued
PricePLN 3.68
Fair ValuePLN 0.39
Quality32/100
Abbott Laboratories
ABT · USD · Health Care
-34%
upside to fair value
overvalued
Price$114
Fair Value$74.79
Quality67/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

GMTAbbott Laboratories
Valuation
P/E (TTM)27.7×
P/S (TTM)3.89×
2.32×P/B3.36×
EV/EBITDA15.1×
PEG1.47×
Dividend yield2.1%
Dividend per share$2.44
Profitability
0%Net margin14%
Operating margin13%
-83%Return on equity12%
-29%Return on assets6%
Growth
220%Revenue growth (YoY)8%
-19.3%Avg. growth/yr (3Y)0.5%
Avg. growth/yr (5Y)5.1%
Balance & size
Debt / equity0.19×
$21MMarket cap$175B
weakGrowth qualityhealthy

Abbott Laboratories leads: 2 to 4 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

GMTof which business quality 32 · market factors 20 Abbott Laboratoriesof which business quality 66 · market factors 55
ProfitabilityMargins and returns on capital today
0
50
Quality GrowthAre margins and returns improving?
56
47
CashflowEarnings quality: real cash, not paper profit
13
71
Fin. StrengthBalance sheet, leverage, solvency risk
97
80
InvestmentDisciplined investing over empire-building
18
65
Low VolatilityCalm price path (market factor)
51
83
MomentumPrice trend over the last 3–12 months (market factor)
7
45
52W MomentumDistance to the 52-week high (market factor)
5
42
Net IssuanceBuybacks instead of dilution
0
84

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

GMT

Asset-BasedPLN 0.36

1 of 1 models see the stock below the current price.

Abbott Laboratories

DCF Models$73.01
Earnings-Based$29.42
Dividend Discount$39.73
Multiples$70.72
Asset-Based$20.05
Growth DCF$67.02
Economic Profit$37.49
Growth Earnings$70.25

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

GMT
Bear PLN 0.26Fair Value PLN 0.39Bull PLN 0.49
PLN 3.68 = current price (white tick)
Abbott Laboratories
Bear $51.13Fair Value $74.79Bull $94.43
$114 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

GMT · Health Care

Quality score32 · bottom 25%
Fair value upside-89% · bottom 25%

Abbott Laboratories · Health Care

Quality score67 · Top 25%
Fair value upside-34% · below median

Bottom line

As of Aug 21, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: GMT trades at PLN 3.68 versus a fair value of PLN 0.39 (-89%), while Abbott Laboratories trades at $114 versus $74.79 (-34%).

Abbott Laboratories has the higher quality score (67/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.